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Abstract 
Autoimmune pancreatitis is a benign disorder 
which frequently presents with symptoms and imaging 
suggestive of pancreatic malignancy.  Up to 21% of 
pancreatoduodenectomies performed for suspected 
pancreatic cancer are found to have benign disease.  
Autoimmune pancreatitis responds rapidly to 
corticosteroids and may be associated with extra-
pancreatic manifestations.  Type 1 forms part of the 
IgG4-related disease while type 2 autoimmune 
pancreatitis is less likely to have elevated levels of IgG4.   
This review discusses the characteristics of the two types 
of autoimmune pancreatitis and highlights the 
management and prognosis of this condition. 
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Autoimmune pancreatitis (AIP) is a benign, 
infrequently recognised disorder which typically 
presents with symptoms and imaging suggestive of 
pancreatic cancer.  It was first classified as a disease 
entity in 1995 and accounts for approximately 2% of 
cases of chronic pancreatitis.  AIP is a great “pretender” 
of pancreatic carcinoma, being found in 2.4% of 
pancreas resection specimens.1 Peak age of onset is in 
the seventh decade with the vast majority of patients 
being older than 45 years.2  
AIP is divided into two types: type 1 or 
lymphoplasmocytic sclerosing pancreatitis and type 2 or 
idiopathic duct centric pancreatitis.  AIP type 1 typically 
affects older patients, is characterised by positivity to 
IgG4 and forms part of the IgG4-related diseases.1  
IgG4-related disease is a rare systemic fibro-
inflammatory disorder which may involve various 
abdominal organs and can lead to autoimmune 
pancreatitis, retroperitoneal fibrosis, sclerosing 
cholangitis, gallbladder pseudotumors, multifocal renal 
abnormalities and sclerosing mesenteritis.  It is 
characterised by abundant infiltration of IgG4+ 
plasmacytes and lymphocytes.3 Extra-pancreatic 
manifestations of IgG4-related disease are common in 
AIP type 1, with 68% of patients having extra-pancreatic 
(usually biliary) involvement.4 
An IgG4 level >210 mg/dl has been shown to have 
the greatest sensitivity (83.8%) and specificity (89.5%) 
for AIP though up to 35.5% of patients with pancreatic 
adenocarcinoma and 25.4% of patients with chronic 
pancreatitis have values >140 mg/dl.  Therefore, 
elevated IgG4 levels alone are not enough to 
differentiate between pancreatic cancer and AIP.5  
Serum IgG4 levels also have a poor positive predictive 
value in the diagnosis of IgG4-related disease with only 
15% of patients with IgG4 levels >130 mg/dl having 
IgG4-related disease.6  A number of cases of type 1 AIP 
without IgG4 tissue infiltration or serum IgG4 elevation 
have also been described, suggesting that AIP should 
also be suspected in patients with normal IgG4 levels.7  
Type 2 AIP typically affects younger patients, is 
confined only to the pancreas and is not associated with 
elevated levels of IgG4.8 Pancreatic histology is 
characterised by granulocytic epithelial infiltration.3  
Patients with type 2 AIP typically present with 
abdominal pain and a tumor-like mass in the pancreas.  
Serum levels of IgG4 are less frequently elevated than in 
type 1 AIP (12% in type 2 versus 55% in type 1), so 
distinguishing from pancreatic cancer is even more 
difficult.9   
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AIP typically presents with clinical features which 
are very suspicious for pancreatic malignancy, including 
obstructive jaundice (50%), abdominal pain (44%), 
fatigue and weight loss (13%).  These symptoms 
frequently prompt surgical intervention.10  Benign lesions 
are found in 5-21% of pancreatoduodenectomies 
performed for suspected neoplasms.11  A study on 
pathological samples in Mainz, Germany showed that 
8.8% of patients (33 patients from a total of 373 
patients) undergoing pancreatoduodenectomy had 
benign disease and 11 patients (33%) with benign 
disease were found to have AIP.11 
 
Work-up for patients with suspected AIP 
Laboratory investigations frequently show deranged 
liver function tests (with a typical obstructive picture).  
Serum immunoglobulin and IgG4 levels are typically 
increased.  Initial imaging (CT scan) and ultrasound 
abdomen will reveal a focally enlarged pancreas (in 38% 
- this increases the suspicion of pancreatic 
adenocarcinoma) or a diffusely enlarged pancreas (in 
62%).  Unfortunately, a good number of these patients 
undergo surgical resection for a condition which can be 
managed medically. Histological analysis typically 
reveals pancreatic interstitial fibrosis with infiltration of 
lymphocytes and plasma cells.10 Pancreatic parenchyma 
is usually infiltrated by immune cells, particularly CD4 
or CD8 T lymphocytes and IgG4-bearing plasma cells.12     
While radiological and clinical findings frequently raise 
the suspicion of pancreatic cancer in patients with AIP, 
specific findings on CT and MRI may help distinguish 
between the two.  Diffuse pancreatic enlargement, 
capsule-like rim and delayed homogenous enhancement 
are more suggestive of AIP.  Main pancreatic duct 
narrowing by >1/3 of the pancreatic length, skipped 
narrowing in the main pancreatic duct and smooth and 
straight intra-pancreatic common bile duct stenosis on 
MRCP are more in keeping with AIP.13  Another 
common finding at MRCP is the presence of multiple, 
long stenoses of the main pancreatic duct without 
dilatation in the remaining portions of the pancreatic 
duct.14 
There is typically a rapid clinical and radiological 
response to treatment with corticosteroids in patients 
with AIP. Pancreatic swelling improves in 83% while 
pancreatic duct irregularities improve in 75% within 2 
weeks of starting corticosteroid therapy.15 
Endoscopic tools in the diagnosis of AIP include 
endoscopic retrograde cholangiopancreatography 
(ERCP) and endoscopic ultrasound (EUS). Endoscopic 
ultrasound images the main pancreatic and common bile 
ducts and also allows sampling of pancreatic tissue for 
histological analysis. Diffuse, irregular narrowing of the 
main pancreatic duct in the absence of upstream 
dilatation from the stricture (<5mm) is a typical finding 
at ERCP, though localized narrowing may be difficult to 
differentiate from stenosis secondary to pancreatic 
cancer.  The main pancreatic duct and common bile duct 
immediately adjacent to the papilla (up to 1.5cms from 
the ampullary orifice) are frequently maintained with no 
narrowing seen in the initial portion of these two ducts.16 
Transpapillary biopsy with IgG4 immunostaining of 
biliary strictures may be necessary to rule out 
cholangiocarcinoma and to reach a diagnosis of IgG4-
sclerosing cholangitis.  IgG4 immunostaining of 
histological specimens from the major papilla may also 
be helpful in diagnosing AIP.17  Biliary stent placement 
during ERCP is important in the initial management of 
AIP with biliary stenting being useful in relieving 
jaundice in 71% of type 1 and 77% of type 2 AIP.18 
EUS allows operators to obtain cytological and 
histological samples by fine needle aspiration.  EUS 
typically shows diffuse hypoechoic pancreatic 
enlargement.  Novel EUS techniques including EUS-
elastography and contrast-enhanced harmonic EUS are 
also able to differentiate between AIP and pancreatic 
cancer, though histological sampling of the pancreas is 
by far considered the gold standard diagnostic 
technique.19 
 
Classification 
Several different classification criteria have been 
devised to diagnose AIP.  The most recent classification 
system (the International Consensus Diagnostic Criteria 
- ICDC) has been shown to have higher sensitivity, 
specificity and accuracy than the older HISORt and 
Asian criteria.20 The ICDC criteria include: 
1. imaging of the pancreatic duct and parenchyma  
2. serology  
3. other organ involvement 
4. pancreatic histology 
5. the optional criterion of response to steroid therapy  
Diagnosis of type 1 or type 2 AIP may be definitive 
or probable depending on the strength of the findings 
and in some cases, one may not be able to distinguish 
between the subtypes (AIP not otherwise specified).  
Imaging and response to steroids is not able to 
distinguish between type 1 and type 2 AIP.  Typical 
serological abnormalities as well as other organ 
involvement are seen only in type 1; however 
inflammatory bowel disease seems to be associated with 
both types.  Absence of serological abnormalities and 
other organ involvement does not necessarily imply a 
diagnosis of type 2 AIP since type 1 may also be 
seronegative and without other organ involvement.21 
Therefore, even with the use of the ICDC criteria, it is 
not always possible to confirm AIP subtype without 
histological analysis of pancreatic tissue.22   
These diagnostic criteria are bound to change 
further.  A recent international symposium on the 
diagnosis of AIP held in Seoul has concluded that there 
is room for improvement in the ICDC and that further 
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modifications might be required in the future.23   
 
Management and Prognosis 
Treatment for AIP should be considered if patients 
develop jaundice, systemic manifestations or persistent 
pain.  Initial treatment is with corticosteroids though 
azathioprine may be necessary if patients relapse on 
tailing down steroids.1 Clinical remission is achieved in 
99% of type 1 and 92% of type 2 AIP with corticosteroid 
therapy.18 The recommended dose of prednisolone for 
induction of remission is 30-40 mg/day tailing down 
over 2-3 months to a maintenance dose of 5-7.5 mg/day 
for a period of 3 years.24   
However, different countries use different tailing 
down regimes of steroids.  In the United States, the 
initial induction dose is of 40 mg prednisolone for 4 
weeks with the steroids being tailed down by 5 mg per 
week until the steroids are stopped completely.25 In 
Japan, the initial induction dose is given for 2-4 weeks, 
after which steroids are tailed down by 5 mg every 1-2 
weeks until a prednisolone dose of 15 mg is reached.  At 
this point, the steroid dose is reduced more slowly (by 
2.5 – 5 mg every 2-8 weeks) until a maintenance dose of 
2.5-5 mg per day is reached.  Researchers from Holland 
have shown that response to low-dose (10-20mg/day), 
medium-dose (30 mg/day) and high-dose (40-60 
mg/day) prednisolone as induction therapy for AIP was 
comparable.26  However, while resolution of pancreatic 
abnormalities is relatively quick, extra-pancreatic lesions 
(retroperitoneal fibrosis, bile duct strictures and ductal 
wall thickening) take more time to resolve and tailing 
down of steroids should therefore be tailored to each 
patient according to the disease activity of all organs 
involved.  
Risk of relapse is high in type 1 (up to 30-50% 
relapse within 6-12 months) while risk of relapse in type 
2 AIP is much less frequent.27  The largest study on AIP 
carried out so far (1064 patients from 23 institutions in 
10 different countries) showed that relapse occurs in 
31% of type 1 and 9% of type 2 AIP.  Remission is 
rapidly achieved on re-introducing corticosteroid 
therapy.18   
Since the sensitivity and specificity of serological 
tests (IgG4 and Ca19.9) and imaging (CT and MRI) in 
distinguishing between AIP and pancreatic cancer is 
low, an important tool in differentiating between the two 
conditions involves the empirical treatment with 
corticosteroids.  AIP exhibits a quick and dramatic 
response to corticosteroids while pancreatic cancer does 
not exhibit such a response.28  
Management of AIP is important not only to manage the 
symptoms associated with this condition but also to 
avoid the development of chronic pancreatitis.  While 
acute phase AIP responds immediately to 
corticosteroids, the long-term prognosis and outcome of 
AIP are still unknown.  Up to 20% of patients progress 
to chronic pancreatitis and AIP is suspected to lead to 
the development of pancreatic duct stones, probably 
secondary to narrowing of the pancreatic ducts.29 
Smoking appears to increase the risk of pancreatic 
damage and increase the risk of diabetes in AIP.   
Smoking cessation should be encouraged in all 
patients.30 
Initial analysis on cancer risk in patients with AIP 
and IgG4 related disorders has revealed no increased 
risk of malignancy in these patients with the cancer risk 
being similar to that of age-and gender-matched 
controls.31-32  However, prospective follow-up of 115 
patients from two large tertiary referral centres in the 
UK showed that both type 1 AIP and IgG4-related 
sclerosing cholangitis are associated with significant 
morbidity and mortality owing to extra-pancreatic organ 
failure and malignancy.33  The largest study on AIP 
carried out to date has shown that pancreatic calculi and 
cancer are rare in type 1 and absent in type 2 AIP.18 
Since AIP is frequently mistaken for pancreatic 
malignancy, it is important to consider whether a biopsy 
of a pancreatic mass lesion should be carried out before 
undertaking major surgery.  With 5-21% of resected 
pancreatic specimens being benign, an international 
panel of pancreatic surgeons working in well-known, 
high-volume centres reviewed the literature and worked 
together to establish a consensus on when to perform a 
pancreatoduodenectomy in the absence of positive 
histology.  Consensus was reached that histological 
proof is not required before surgical resection in the 
presence of a solid mass suspicious for malignancy.  
However, malignancy should always be confirmed 
histologically (preferably by EUS-guided FNA or 
biopsy) for patients with borderline resectable disease 
who need treatment with neoadjuvant therapy before 
exploration for resection.  A biopsy is also 
recommended when a diagnosis of AIP is highly 
suspected and a short course of steroids considered if the 
biopsy does not suggest malignancy.34 
 
Conclusion 
AIP is the great “pretender” of pancreatic 
malignancy.  Increasing awareness of the clinical, 
radiological, serological and extra-pancreatic 
involvement associated with this disorder may allow 
early recognition and avoid unnecessary surgery for this 
benign condition.  Better classification criteria and a 
standardised therapeutic plan with corticosteroids and 
other immune-suppressants are needed in AIP. 
 
References 
1. Rasch S, Phillip V, Weirich G, Esposito I, Gaa J, Schmid RM, 
et al. Autoimmune pancreatitis - treatment and pitfalls in 
diagnostics. Internist (Berl). 2014 Aug 8. 
 
 
 
46
  
 
 
 
Review Article  
 
 
Malta Medical Journal    Volume 26 Issue 04 2014                                                                                                                
 
 
2. Nishimori I, Tamakoshi A, Otsuki M; Research Committee on 
Intractable Diseases of the Pancreas, Ministry of Health, 
Labour, and Welfare of Japan. Prevalence of autoimmune 
pancreatitis in Japan from a nationwide survey in 2002. J 
Gastroenterol. 2007;42 Suppl 18:6-8. 
3. Okazaki K, Tomiyama T, Mitsuyama T, Sumimoto K, Uchida 
K. Diagnosis and classification of autoimmune pancreatitis. 
Autoimmun Rev. 2014;13(4-5):451-8. 
4. Chatterjee S, Oppong KW, Scott JS, Jones DE, Charnley RM, 
Manas DM, et al. Autoimmune pancreatitis - diagnosis, 
management and longterm follow-up. Gastrointestin Liver Dis. 
2014;23(2):179-85. 
5. Talar-Wojnarowska R, Gąsiorowska A, Olakowski M, Dranka-
Bojarowska D, Lampe P, Smigielski J, et al. Utility of serum 
IgG, IgG4 and carbonic anhydrase II antibodies in 
distinguishing autoimmune pancreatitis from pancreatic cancer 
and chronic pancreatitis. Adv Med Sci. 2014;59(2):288-292.  
6. Yun J, Wienholt L, Adelstein S.  Poor positive predictive value 
of serum immunoglobulin G4 concentrations in the diagnosis 
of immunoglobulin G4-related sclerosing disease.  Asia Pac 
Allergy. 2014;4(3):172-6. 
7. Hart PA, Smyrk TC, Chari ST. Lymphoplasmacytic sclerosing 
pancreatitis without IgG4 tissue infiltration or serum IgG4 
elevation: IgG4-related disease without IgG4. Mod Pathol. 
2014 Aug 1.  
8. Morse B, Centeno B, Vignesh S. Autoimmune Pancreatitis: 
Updated Concepts of a Challenging Diagnosis. Am J Med. 
2014 May 14.  
9. Fritz S, Bergmann F, Grenacher L, Sgroi M, Hinz U, Hackert 
T, Büchler MW, Werner J. Diagnosis and treatment of 
autoimmune pancreatitis types 1 and 2. Br J Surg. 
2014;101(10):1257-65. 
10. Chen D, Cao H, Chen Y, Li Y, Yu C. The clinical 
characteristics of 32 patients with autoimmune pancreatitis. 
Zhonghua Nei Ke Za Zhi. 2014;53(5):380-3. 
11. Vitali F, Hansen T, Kiesslich R, Heinrich S, Kumar A, 
Mildenberger P, et al. Frequency and Characterization of 
Benign Lesions in Patients Undergoing Surgery for the 
Suspicion of Solid Pancreatic Neoplasm. Pancreas. 2014 Jul 23.  
12. Pezzilli R, Pagano N. Pathophysiology of autoimmune 
pancreatitis. World J Gastrointest Pathophysiol. 2014;5(1):11-
7. 
13. Shin JU, Lee JK, Kim KM, Lee KH, Lee KT, Kim YK,et al. 
The differentiation of autoimmune pancreatitis and pancreatic 
cancer using imaging findings. Hepatogastroenterology. 
2013;60(125):1174-81. 
14. Negrelli R, Manfredi R, Pedrinolla B, Boninsegna E, Ventriglia 
A, Mehrabi S, et al. Pancreatic duct abnormalities in focal 
autoimmune pancreatitis: MR/MRCP imaging findings. Eur 
Radiol. 2014 Aug 9.  
15. Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, 
Ishigaki T, et al. Timing of radiological improvement after 
steroid therapy in patients with autoimmune pancreatitis. Scand 
J Gastroenterol. 2014;49(6):727-33. 
16. Iwasaki S, Kamisawa T, Koizumi S, Chiba K, Tabata T, 
Kuruma S, et al. Characteristic Findings of Endoscopic 
Retrograde Cholangiopancreatography in Autoimmune 
Pancreatitis.  Gut Liver. 2014 Jun 18.  
17. Kamisawa T, Ohara H, Kim MH, Kanno A, Okazaki K, Fujita 
N. Role of endoscopy in the diagnosis of autoimmune 
pancreatitis and immunoglobulin G4-related sclerosing 
cholangitis. Dig Endosc. 2014 Apr 8. 
18. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, 
Czakó L, et  al.  Long-Term Outcomes of Autoimmune 
Pancreatitis: A Multicentre, International Analysis. Gut 
2013;62(12)1771-1776. 
 
 
19. Kanno A, Masamune A, Shimosegawa T. Endoscopic 
approaches for the diagnosis of autoimmune pancreatitis. Dig 
Endosc. 2014 Aug 13. 
20. Chang MC, Liang PC, Jan IS, Yang CY, Tien YW, Wei SC, et 
al. Comparison and validation of International Consensus 
Diagnostic Criteria for diagnosis of autoimmune pancreatitis 
from pancreatic cancer in a Taiwanese cohort. BMJ Open. 
2014;4(8):e005900. 
21. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, 
Mino-Kenudson M, et al. International Consensus Diagnostic 
Criteria for Autoimmune Pancreatitis: Guidelines of the 
International Association of Pancreatology.  Pancreas 
2011;40(3):352-358. 
22. Ikeura T, Detlefsen S, Zamboni G, Manfredi R, Negrelli R, 
Amodio A, et al. Retrospective comparison between 
preoperative diagnosis by International Consensus Diagnostic 
Criteria and histological diagnosis in patients with focal 
autoimmune pancreatitis who underwent surgery with 
suspicion of cancer. Pancreas. 2014;43(5):698-703.  
23. Song TJ, Kim MH, Kim MJ, Moon SH, Han JM; International 
Panel of Speakers and Moderators. Clinical validation of the 
international consensus diagnostic criteria and algorithms for 
autoimmune pancreatitis: combined IAP and KPBA meeting 
2013 report. Pancreatology. 2014;14(4):233-7.  
24. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, 
Watanabe H, Kanno A, et al. Standard steroid treatment for 
autoimmune pancreatitis. Gut 58:1504-1507, 2009. 
25. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, 
et al. Differences in clinical profile and relapse rate of type 1 
versus type 2 autoimmune pancreatitis. Gastroenterology 
139:140-148, 2010. 
26. Buijs J, van Heerde MJ, Rauws EA, de Buy Wenniger LJ, 
Hansen BE, Biermann K, et al. Comparable efficacy of low- 
versus high-dose induction corticosteroid treatment in 
autoimmune pancreatitis. Pancreas. 2014;43(2):261-7.  
27. Okazaki K, Uchida K, Sumimoto K, Mitsuyama T, Ikeura T, 
Takaoka M. Autoimmune pancreatitis: pathogenesis, latest 
developments and clinical guidance. Ther Adv Chronic Dis. 
2014;5(3):104-11. 
28. Berger Z. Focal autoimmune pancreatitis versus pancreatic 
cancer: value of steroid treatment in the diagnosis. Rev Med 
Chil. 2014;142(4):413-7. 
29. Maruyama M, Watanabe T, Kanai K, Oguchi T, Asano J, Ito T, 
et al. Autoimmune pancreatitis can develop into chronic 
pancreatitis. Orphanet J Rare Dis. 2014;9:77. 
30. Maire F, Rebours V, Vullierme MP, Couvelard A, Lévy P, 
Hentic O, et al. Does tobacco influence the natural history of 
autoimmune pancreatitis? Pancreatology. 2014;14(4):284-8. 
31. Hart PA, Law RJ, Dierkhising RA, Smyrk TC, Takahashi N, 
Chari ST. Risk of cancer in autoimmune pancreatitis: a case-
control study and review of the literature. Pancreas. 
2014;43(3):417-21.  
32. Hirano K, Tada M, Sasahira N, Isayama H, Mizuno S, Takagi 
K, et al. Incidence of malignancies in patients with IgG4-
related disease. Intern Med. 2014;53(3):171-6. 
33. Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo 
M, Chapman MH, et al. Type 1 Autoimmune Pancreatitis and 
IgG4-Related Sclerosing Cholangitis Is Associated With 
Extrapancreatic Organ Failure, Malignancy, and Mortality in a 
Prospective UK Cohort. Am J Gastroenterol. 2014 Aug 26. 
34. Asbun HJ, Conlon K, Fernandez-Cruz L, Friess H, Shrikhande 
SV, Adham M et al; International Study Group of Pancreatic 
Surgery. When to perform a pancreatoduodenectomy in the 
absence of positive histology? A consensus statement by the 
International Study Group of Pancreatic Surgery. Surgery. 
2014;155(5):887-92. 
 
 
47
